Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures dip after AI rout, telecoms slide
- Brent crude hits more than five-month high on concern over Middle East escalation
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $10.53 million versus the consensus estimate of $11.24 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Gorman-Rupp (GRC) Tops Q3 EPS by 16c, Beats on Revenue
- Cass Information Systems (CASS) Tops Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
